Replies to post #99995 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

I am not the first person to fault the FDA for being slow and inefficient and I won’t be the last. And it is not limited to affecting ADXS. Why did ADXS (most likely Mauro) design the trial this way? It is not a matter of simply unilaterally designing a trial when you apply for SPA. There is an ongoing discussion/negotiation with the FDA in arriving at what is approvable. So there’s your answer.

[Bourbon_on_my_cornflakes]

Understand DOC's ADXS game plan when you look at things like
a failure to include an interim look provision in the original SPA.

DOC's game plan was clear. He was in no rush to get anything approved, and wanted to keep it all for ADXS instead of getting money partners. Hence the trials with Merck, BMY, Astra where ADXS paid all the costs. Hence the cruddy little partners in Asia and Latin America and Canada, to give the look of progress while ADXS kept it all.

The goal was to keep it all, take a lot of time, and allow DOC to eventually own 20-40% of the company through endless stock options. That way when ADXS was sold for $10 billion, $2-4 billion would got directly into DOC's bank account.

The fatal flaw in the plan was DOC's assumption that he could keep making dilutions at the $15-20 pre-split ($225-$300 post R/S) share level to underwrite this for years.

The market wasn't stupid, and quashed this greedy DOC delusion by crushing the stock price to nothing.